Tanabe Pharma America, a subsidiary of the Tanabe Pharma Corporation, is not the only company developing drugs for EPP and ...

The UK DRI has announced an international research study to assess whether a finger-prick blood test could help diagnose ...

Analysis published in the American Society of Nephrology highlighted strong evidence that ERAs benefit chronic kidney disease ...

Adalyon’s CEO, Ulrik Zeuthen, notes that speech-based biomarkers can be used across several applications to optimise trial ...

The FDA and EMA's joint guidance was created to ensure the pharmaceutical industry employs best practices when using AI in ...

Axsome Therapeutics has initiated the FORWARD Phase III trial evaluating AXS-14 for the management of fibromyalgia, with the ...

Intellia Therapeutics CEO John Leonard explained the circumstances of the patient death at the J.P. Morgan Healthcare ...

Sanofi's amlitelimab has shown promise in the Phase III COAST 1 trial, but data from the COAST 2 study is yet to be announced ...

The UK has announced new clinical trial regulatory reforms to boost its appeal as a leading destination for medical research.

Clinical and commercial quality controls are eased as the FDA looks to expedite therapy approvals in areas of unmet need.

Atea showcased its Phase III HCV programme at JPM, positioning the regimen for test-and-treat adoption in 1,800 patients.

NRG Therapeutics has dosed the first participants in its Phase I clinical trial of NRG5051, being developed as a ...